155 related articles for article (PubMed ID: 30862147)
1. [Clinical effect of icotinib in treatment of elderly advanced non-small cell lung cancer patients with EGFR mutations].
Ren YL; Sheng J; Zhou XY; Fang Y; Pan HM
Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):152-153. PubMed ID: 30862147
[No Abstract] [Full Text] [Related]
2. [Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified].
Song Z; Yu X; Cai J; Shao L; Lin B; He C; Zhang B; Zhang Y
Zhongguo Fei Ai Za Zhi; 2013 Mar; 16(3):138-43. PubMed ID: 23514942
[TBL] [Abstract][Full Text] [Related]
3. Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study.
Lei L; Wang WX; Zhu YC; Li JL; Fang Y; Wang H; Zhuang W; Zhang YB; Wang LP; Fang MY; Xu CW; Wang XJ; Lv TF; Song Y
Cancer Sci; 2020 Feb; 111(2):679-686. PubMed ID: 31828849
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic characteristics and outcome of patients with different EGFR mutations.
Zhou S; Hu X; Wang Y; Li J; Zhou L; Hao X; Liu Y; Shi Y
Asia Pac J Clin Oncol; 2019 Jun; 15(3):166-171. PubMed ID: 30311393
[TBL] [Abstract][Full Text] [Related]
5. Icotinib alone or with bevacizumab as first-line therapy in Chinese patients with advanced nonsquamous non-small cell lung cancer and activating EGFR mutations: A retrospective study.
Jiang Z; Zhang J; Sun H; Wang C; Zhang Y; Li Y; Pan Z
Thorac Cancer; 2021 Sep; 12(17):2369-2374. PubMed ID: 34255422
[TBL] [Abstract][Full Text] [Related]
6. Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes.
Pan H; Liu R; Li S; Fang H; Wang Z; Huang S; Zhou J
Cell Biochem Biophys; 2014 Sep; 70(1):553-8. PubMed ID: 24777808
[TBL] [Abstract][Full Text] [Related]
7. Icotinib plus osimertinib overcome epidermal growth factor receptor 19del/T790 M/C797S/V834L quadruplet resistance mutation in a patient with non-small cell lung cancer.
Zhu C; You YH; Nie KK; Ji YX
Chin Med J (Engl); 2019 May; 132(9):1115-1116. PubMed ID: 31033571
[No Abstract] [Full Text] [Related]
8. A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).
Hu X; Han B; Gu A; Zhang Y; Jiao SC; Wang CL; He J; Jia X; Zhang L; Peng J; Wu M; Ying K; Wang J; Ma K; Zhang S; You C; Tan F; Wang Y; Ding L; Sun Y
Lung Cancer; 2014 Nov; 86(2):207-12. PubMed ID: 25261231
[TBL] [Abstract][Full Text] [Related]
9. [China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2015 version)].
Shi Y; Sun Y; Ding C; Wang Z; Wang C; Wang Z; Bai C; Bai C; Feng J; Liu X; Li F; Yang Y; Shu Y; Wu M; He J; Zhang Y; Zhang S; Chen G; Luo H; Luo R; Zhou C; Zhou Y; Pang Q; Zhao H; Zhao Q; Gu A; Ling Y; Huang C; Han B; Jiao S; Jian H
Zhongguo Fei Ai Za Zhi; 2015 Jul; 18(7):397-400. PubMed ID: 26182862
[No Abstract] [Full Text] [Related]
10. Icotinib: efficacy in different solid tumors and gene mutations.
Zhao Q; Cheng J; Chen P; Sun J; Guan S
Anticancer Drugs; 2020 Mar; 31(3):205-210. PubMed ID: 31934888
[TBL] [Abstract][Full Text] [Related]
11. [China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment
(2016 version)].
Shi Y; Sun Y; Ding C; Wang Z; Wang C; Bai C; Bai C; Feng J; Liu X; Li F; Yang Y; Shu Y; Wu M; He J; Zhang Y; Zhang S; Chen G; Luo H; Luo R; Zhou C; Pang Q; Hu X; Zhao H; Zhao Q; Gu A; Ling Y; Huang C; Han B; Jiao S; Jian H
Zhongguo Fei Ai Za Zhi; 2016 Jul; 19(7):489-94. PubMed ID: 27339727
[No Abstract] [Full Text] [Related]
12. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.
Shi Y; Zhang L; Liu X; Zhou C; Zhang L; Zhang S; Wang D; Li Q; Qin S; Hu C; Zhang Y; Chen J; Cheng Y; Feng J; Zhang H; Song Y; Wu YL; Xu N; Zhou J; Luo R; Bai C; Jin Y; Liu W; Wei Z; Tan F; Wang Y; Ding L; Dai H; Jiao S; Wang J; Liang L; Zhang W; Sun Y
Lancet Oncol; 2013 Sep; 14(10):953-61. PubMed ID: 23948351
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of icotinib in advanced lung squamous cell carcinoma.
Liang S; Xu Y; Tan F; Ding L; Ma Y; Wang M
Cancer Med; 2018 Sep; 7(9):4456-4466. PubMed ID: 30109777
[TBL] [Abstract][Full Text] [Related]
14. Influence of wellness education on first-line icotinib hydrochloride patients with stage IV non-small cell lung cancer and their family caregivers.
Yanwei L; Minghui F; Manman Q; Zhuchun Y; Dongying L; Zhanyu P
Curr Probl Cancer; 2018; 42(3):358-366. PubMed ID: 29731164
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
Lu S; Ye M; Ding L; Tan F; Fu J; Wu B
Oncotarget; 2017 Feb; 8(6):9996-10006. PubMed ID: 28036283
[TBL] [Abstract][Full Text] [Related]
16. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
Yang JJ; Zhou C; Huang Y; Feng J; Lu S; Song Y; Huang C; Wu G; Zhang L; Cheng Y; Hu C; Chen G; Zhang L; Liu X; Yan HH; Tan FL; Zhong W; Wu YL
Lancet Respir Med; 2017 Sep; 5(9):707-716. PubMed ID: 28734822
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of icotinib versus traditional chemotherapy as first-line treatment for preventing brain metastasis from advanced lung adenocarcinoma in patients with epidermal growth factor receptor-sensitive mutation.
Zhao X; Zhu G; Chen H; Yang P; Li F; Du N
J Cancer Res Ther; 2014 Nov; 10 Suppl():C155-9. PubMed ID: 25450275
[TBL] [Abstract][Full Text] [Related]
18. Lung adenocarcinoma patient with EGFR 19 exon insert mutation and its response to icotinib.
Zhu YC; Du KQ; Wang WX; Song ZB; Xu CW; Chen G; Zhuang W; Lv TF; Song Y
Lung Cancer; 2018 Jul; 121():101-104. PubMed ID: 29773459
[No Abstract] [Full Text] [Related]
19. Efficacy of icotinib versus traditional chemotherapy as first-line treatment for preventing brain metastasis from advanced lung adenocarcinoma in patients with epidermal growth factor receptor-sensitive mutation.
Zhao X; Zhu G; Chen H; Yang P; Li F; Du N
J Cancer Res Ther; 2016; 12(3):1127-1131. PubMed ID: 28054523
[TBL] [Abstract][Full Text] [Related]
20. [Clinical observation of icotinib hydrochloride for patients with advanced non-small cell lung cancer].
Li X; Yang XJ; Sun YF; Qin N; Lü JL; Wu YH; Zhang H; Zhang Q; Zhang SC
Zhonghua Zhong Liu Za Zhi; 2012 Aug; 34(8):627-31. PubMed ID: 23159001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
